Development of a polymer system for the delivery of daunorubicin to tumor cells to overcome drug resistance


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Method for the synthesis of polymeric nanoparticles (NP) with encapsulated daunorubicin (DNR) was developed on the basis of double emulsion solvent evaporation technique using biodegradable poly(lactide-co-glycolide) (PLGA), which is aimed at customization of pharmacokinetic properties of the preparation, enhanced accumulation of DNR in tumor cells and prolongation of its action. The obtained polymer nanoparticles (DNR-PLGA) had average size ranging around 138±36 nm, with zeta-potential of –25.3 mV and the polydispersity index (PDI) of 0.072. The release kinetics of DNR from polymer nanoparticles at pH 7.4 and 5.0 has been studied. In vitro studies showed similar specific activity of DNR- PLGA in K562 and MCF-7 cancer cell lines together with an increase in activity in K562 Adr and MCF-7 Adr cell lines, which are anthracycline resistant, by 1.6 and 3.4 times. The study demonstrated the efficacy of the developed PLGA-based DNR delivery system in the improvement of antitumor effect of DNR, overcoming multidrug resistance in cancer cells, and also in the decrease in nonspecific toxicity of the preparation.

Sobre autores

E. Nikolskaya

Moscow Technological University, M. V. Lomonosov Institute for Fine Chemical Technologies

Email: e.sverin@mail.ru
Rússia, 86 prosp. Vernadskogo, Moscow, Russian Federation, 119571

M. Faustova

Moscow Technological University, M. V. Lomonosov Institute for Fine Chemical Technologies

Email: e.sverin@mail.ru
Rússia, 86 prosp. Vernadskogo, Moscow, Russian Federation, 119571

M. Mollaev

Moscow Technological University, M. V. Lomonosov Institute for Fine Chemical Technologies

Email: e.sverin@mail.ru
Rússia, 86 prosp. Vernadskogo, Moscow, Russian Federation, 119571

O. Zhunina

Russian Research Center for Molecular Diagnostics and Therapy

Email: e.sverin@mail.ru
Rússia, 8 Simpheropol’sky bulvar, Moscow, Russian Federation, 117149

M. Sokol

Russian Research Center for Molecular Diagnostics and Therapy

Email: e.sverin@mail.ru
Rússia, 8 Simpheropol’sky bulvar, Moscow, Russian Federation, 117149

N. Yabbarov

Russian Research Center for Molecular Diagnostics and Therapy

Email: e.sverin@mail.ru
Rússia, 8 Simpheropol’sky bulvar, Moscow, Russian Federation, 117149

N. Gukasova

National Research Center Kurchatov Institute

Email: e.sverin@mail.ru
Rússia, 1 pl. Akad. Kurchatova, Moscow, Russian Federation, 123182

A. Lobanov

N. N. Semenov Institute of Chemical Physics, Russian Academy of Sciences

Email: e.sverin@mail.ru
Rússia, 4 ul. Kosygina, Moscow, Russian Federation, 119991

V. Shvets

Moscow Technological University, M. V. Lomonosov Institute for Fine Chemical Technologies

Autor responsável pela correspondência
Email: shvetsviiv@gmail.com
Rússia, 86 prosp. Vernadskogo, Moscow, Russian Federation, 119571

E. Severin

Russian Research Center for Molecular Diagnostics and Therapy

Autor responsável pela correspondência
Email: e.sverin@mail.ru
Rússia, 8 Simpheropol’sky bulvar, Moscow, Russian Federation, 117149

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2018